RxDoctor Payments Data

Kevin Cope, MD

Family Medicine · Broadalbin, NYNPI 1861498248

Payments from drug & device makers

$836in general payments, 2019–2025

Across 44 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$155
  • Novo Nordisk$116
  • Boehringer Ingelheim$112
  • AstraZeneca$60
  • AbbVie$60
  • Indivior Inc.$58
  • plus $275 from 15 others

What the payments were for

  • Food & beverage$81597%
  • Education$213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$836 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$133,977
Medicare patients
349
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$126,717
EliquisApixaban150$125,956
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl309$65,813
FarxigaDapagliflozin Propanediol46$65,337
JardianceEmpagliflozin46$65,120
TrulicityDulaglutide48$51,904
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$44,467
MounjaroTirzepatide28$40,755
XareltoRivaroxaban43$37,695
ProliaDenosumab18$32,538
Tresiba Flextouch U-100Insulin Degludec18$29,919
LinzessLinaclotide27$19,481
Breo ElliptaFluticasone/Vilanterol32$15,878
Pregabalin148$11,761
Rosuvastatin Calcium475$11,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$30$136,193162 claims
Novo NordiskOzempic$116$126,717109 claims
AstraZenecaFarxiga, Symbicort$60$73,78066 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$21$65,813309 claims
Boehringer IngelheimJardiance$112$65,12046 claims
Johnson & JohnsonXarelto, Invokana$12$46,65156 claims
AbbVieLinzess, Synthroid$60$25,01778 claims
Indivior Inc.Suboxone$58$10,56020 claims
MerckJanuvia$27$10,51512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Broadalbin

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →